Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297552 | 0.85 | TDP1 (0.66) | PLAUHDAC6HDAC8HDAC2CA2 | |
| SCHEMBL2635910 | 0.85 | HDAC6 (0.62) | HDAC6HDAC8HDAC2MAPTTDP1 | |
| SCHEMBL940919 | 0.84 | PLAU (0.53) | PLAUHDAC6HDAC8HDAC2CA2 | |
| SCHEMBL29582662 | 0.84 | PLAU (0.53) | PLAUHDAC6HDAC8HDAC2CA2 | |
| Hydrochloric Acid SCHEMBL3176039 | 0.83 | TDP1 (0.63) | PLAUHDAC6HDAC8HDAC2CA2 | |
| SCHEMBL4141704 | 0.82 | KMT2A (0.56) | PLAUHDAC6HDAC8HDAC2MAPT | |
| SCHEMBL17744810 | 0.81 | NPC1 (0.58) | MAPTTDP1SMN1; SMN2HDAC1NPC1 | |
| SCHEMBL8507005 | 0.81 | HDAC6 (0.53) | PLAUHDAC6HDAC8HDAC2CA2 | |
| SCHEMBL30871249 | 0.81 | HDAC1 (0.52) | PLAUHDAC6HDAC8HDAC2CA2 | |
| SCHEMBL30107275 | 0.81 | HDAC6 (0.53) | PLAUHDAC6HDAC8HDAC2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-09 | — | — | US | disclosed |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-26 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9795607-B2 | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3202403-A1 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2945636-B1 | SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763629-B2 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-03-05 | — | — | US | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | PLAU 3822/4885HDAC6 3132/4885HDAC8 3246/4885 |
| US-20090062292-A1 | Tetrahydropteridines useful as inhibitors of protein kinases | PRKCH, DMPK, MAP3K20 | PLAU 2056/4885HDAC6 3294/4885HDAC8 4640/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PLAU 4165/4885HDAC6 1604/4885HDAC8 3493/4885 |
| US-11396517-B1 | Exo-aza spiro inhibitors of menin-MLL interaction | BMI1, MLLT1, EED | PLAU 3477/4885HDAC6 1009/4885HDAC8 647/4885 |
| US-20110021519-A1 | TETRAHYDROPTERIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES | PRKCH, DMPK, MAP3K20 | PLAU 2056/4885HDAC6 3294/4885HDAC8 4640/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PLAU 3956/4885HDAC6 1677/4885HDAC8 3648/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PLAU 3956/4885HDAC6 1677/4885HDAC8 3648/4885 |
| US-20230039917-A1 | EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION | BMI1, MLLT1, SUZ12 | PLAU 3202/4885HDAC6 915/4885HDAC8 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.